Clinical trial NCT05740566: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Official title: A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Small Cell Lung Cancer (SCLC)
Keywords: Small Cell Lung Cancer
SCLC
AMG 757
Tarlatamab
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2023-02-23
Enrollment: 509
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).


Eligibility criteria: Inclusion Criteria:

* Participant has provided informed consent prior to initiation of any study specific activities/procedures.
* Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
* Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
* Participants who progressed or recurred following 1 platinum-based regimen.
* Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
* Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
* Minimum life expectancy of 12 weeks.
* Adequate organ function.

Exclusion Criteria:

* Disease Related

  * Symptomatic central nervous system (CNS) metastases with exceptions defined in the protocol.
  * Diagnosis or evidence of leptomeningeal disease.
  * Prior history of immune checkpoint inhibitors resulting in events defined in the protocol.
* Other Medical Conditions

  * Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy.
  * History of solid organ transplantation.
  * History of other malignancy within the past 2 years, with exceptions defined in the protocol.
  * Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 12 months prior to first dose of study treatment.
  * History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months prior to first dose of study treatment.
  * Presence or history of viral infection based on criteria per protocol.
  * Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to first dose of study treatment.
  * Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment.
  * Evidence of interstitial lung disease or active, non-infectious pneumonitis.
* Prior/Concomitant Therapy

  * Prior therapy with tarlatamab or any of the standard of care chemotherapy included as part of this trial or participation in any tarlatamab or any other DLL3 targeted agent clinical trial.
  * Prior therapy with any selective inhibitor of the DLL3 pathway.
  * Participant received more than one prior systemic therapy regimen for SCLC.
  * Prior anti-cancer therapy within 21 days prior to first dose of study treatment with exceptions defined in protocol.
  * Current anti-cancer therapy such as chemotherapy, immunotherapy, or targeted therapy with exceptions.
  * Use of herbal or prescription/non-prescription medications known to inhibit membrane transporters P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) within 7 days prior to the first dose of study treatment.
  * Use of herbal or prescription/non-prescription medications known to be moderate or strong inhibitors of cytochrome P450 3A (CYP3A) enzymes within 7 days prior to the first dose of study treatment.
  * Use of herbal or prescription/non-prescription medications known to be moderate or strong inducers of CYP3A enzymes within 28 days prior to first dose of study treatment.
  * Participants who have reached the limit dose of prior treatment with cardiotoxic drugs.
  * Major surgical procedures within 28 days prior to first dose of study treatment.
  * Live and live-attenuated vaccines within 14 days prior to the start of study treatment.
  * Inactive vaccines and live viral non-replicating vaccines within 3 days prior to the first dose of study treatment.
  * Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
* Diagnostic Assessments

  * Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, with exceptions defined in the protocol.
* Other Exclusions

  * Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
  * Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of tarlatamab.
  * Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of tarlatamab.
  * Female participants of childbearing potential with a positive pregnancy test assessed at screening by a serum pregnancy test.
  * Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
  * Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of tarlatamab.
  * Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of tarlatamab.
  * Contraception requirements for male and female participants receiving SOC therapies are based on regional prescribing information.
  * Breastfeeding restrictions for female participants receiving SOC therapies are based on regional prescribing information.
  * Participant has known sensitivity or is contraindicated to any of the products or components to be administered during dosing.
  * Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures.
  * History or evidence of any other clinically significant disorder, condition or disease determined by the investigator or Amgen physician that would pose a risk to the subject safety or interfere with the study evaluation..

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: Up to approximately 4 years
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Up to approximately 4 years
measure: Change from Baseline In Selected Functional Scales and Disease Symptom Items Included in Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
timeFrame: Up to approximately 4 years
measure: Change from Baseline in Selected Disease Symptoms Included in Lung Cancer Quality of Life Questionnaire (EORTC-QLQ-LC13)
timeFrame: Up to approximately 4 years
measure: Overall Response (OR)
timeFrame: Up to approximately 4 years
measure: Disease Control (DC)
timeFrame: Up to approximately 4 years
measure: Duration of Response (DOR)
timeFrame: Up to approximately 4 years
measure: PFS
timeFrame: 1 year
measure: OS
timeFrame: 1 year, 2 years and 3 years
measure: Incidence of Treatment-Emergent Adverse Events (TEAE)
timeFrame: Up to approximately 4 years
measure: Serum Concentrations of Tarlatamab
timeFrame: Up to 1 year
measure: Number of Participants Who Experience Anti-tarlatamab Antibodies
timeFrame: Up to 1 year
measure: Change from Baseline in Pain Severity as Measured by Brief Pain Inventory - Short Form (BPI-SF)
timeFrame: Up to approximately 4 years
measure: Patient Perceived Health at Each Assessment Visit Using Visual Analogue Scale (VAS)
timeFrame: Up to approximately 4 years
measure: Change from Baseline in Patient Perceived Health Using Visual Analog Scale (VAS)
timeFrame: Up to approximately 4 years
measure: Responses to Patient-Reported Adverse Events Questionnaire (PRO-CTCAE)
timeFrame: Up to approximately 4 years
measure: Change from Baseline in Symptom Severity as Measured by Patient Global Impression of Severity (PGIS) Questionnaire
timeFrame: Up to approximately 4 years
measure: Change from Baseline in Symptoms and Overall Status as Measured by Patient Reported Impression of Change (PGIC) Questionnaire
timeFrame: Up to approximately 4 years
measure: Change from Baseline in Symptom Bother as Measured by Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire
timeFrame: Up to approximately 4 years
Other outcomes:
Locations:
city: Mobile
country: United States
facility: University of South Alabama Mitchell Cancer Institute
state: Alabama
city: Anchorage
country: United States
facility: Alaska Oncology and Hematology
state: Alaska
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
city: Santa Monica
country: United States
facility: University of California Los Angeles
state: California
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: Chicago
country: United States
facility: University of Illinois Chicago
state: Illinois
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Pikeville
country: United States
facility: Pikeville Medical Center
state: Kentucky
city: Baton Rouge
country: United States
facility: Our Lady of the Lake Cancer Institute
state: Louisiana
city: Ann Arbor
country: United States
facility: Trinity Health Saint Joseph Mercy Ann Arbor
state: Michigan
city: Minneapolis
country: United States
facility: University of Minnesota Cancer Center
state: Minnesota
city: Columbia
country: United States
facility: University of Missouri Health Care
state: Missouri
city: Summit
country: United States
facility: Summit Medical Group, Overlook Oncology Center
state: New Jersey
city: New York
country: United States
facility: New York University Grossman School of Medicine and New York University Langone Hospitals
state: New York
city: New York
country: United States
facility: Perlmutter Cancer Center at New York University Langone Hospital----Long Island
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Northport
country: United States
facility: Northport Veterans Affairs Medical Center
state: New York
city: Fargo
country: United States
facility: Sanford Roger Maris Cancer Center
state: North Dakota
city: Sioux Falls
country: United States
facility: Sanford Oncology Clinic and Pharmacy
state: South Dakota
city: Knoxville
country: United States
facility: University of Tennessee Medical Center Knoxville
state: Tennessee
city: Memphis
country: United States
facility: Baptist Cancer Center
state: Tennessee
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: Edmonds
country: United States
facility: Swedish Cancer Institute Medical Oncology
state: Washington
city: Milwaukee
country: United States
facility: The Medical College of Wisconsin
state: Wisconsin
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: Cemic
state: Buenos Aires
city: Pilar
country: Argentina
facility: Hospital Universitario Austral
state: Buenos Aires
city: Cordoba
country: Argentina
facility: Sociedad de Beneficencia Hospital Italiano
state: Córdoba
city: Viedma
country: Argentina
facility: Clinica Viedma
state: Río Negro
city: Rosario
country: Argentina
facility: Sanatorio Parque SA
state: Santa Fe
city: Buenos Aires
country: Argentina
facility: Instituto Argentino de Diagnostico y Tratamiento IADT
city: Córdoba
country: Argentina
facility: Sanatorio Allende
city: Liverpool
country: Australia
facility: Liverpool Hospital
state: New South Wales
city: Waratah
country: Australia
facility: Calvary Mater Newcastle Hospital
state: New South Wales
city: Clayton
country: Australia
facility: Monash Medical Centre
state: Victoria
city: Melbourne
country: Australia
facility: The Alfred Hospital
state: Victoria
city: Graz
country: Austria
facility: Medizinische Universitaet Graz
city: Krems
country: Austria
facility: Universitaetsklinikum Krems
city: Gent
country: Belgium
facility: Universitair Ziekenhuis Gent
city: Hasselt
country: Belgium
facility: Jessa Ziekenhuis - Campus Virga Jesse
city: Roeselare
country: Belgium
facility: AZ Delta Campus Rumbeke
city: Sint-Niklaas
country: Belgium
facility: Vitaz campus Sint-Niklaas Moerland
city: Salvador
country: Brazil
facility: Hospital Santa Izabel
state: Bahia
city: Salvador
country: Brazil
facility: Instituto de Ensino e Pesquisa do Hospital da Bahia
state: Bahia
city: Natal
country: Brazil
facility: Liga Norte-Riograndense Contra O Cancer
state: Rio Grande Do Norte
city: Ijui
country: Brazil
facility: Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
facility: Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul
state: Rio Grande Do Sul
city: Porto Velho
country: Brazil
facility: Hospital de Amor da Amazonia
state: Rondônia
city: Sao Paulo
country: Brazil
facility: Beneficencia Portuguesa de Sao Paulo - Bp
state: São Paulo
city: Sao Paulo
country: Brazil
facility: Oncologia Rede D Or
state: São Paulo
city: São José do Rio Preto
country: Brazil
facility: Hospital de Base de Sao Jose do Rio Preto
state: São Paulo
city: Rio de Janeiro
country: Brazil
facility: Instituto Coi
city: São Paulo
country: Brazil
facility: Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp
city: London
country: Canada
facility: London Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
city: Hefei
country: China
facility: Anhui Chest Hospital
state: Anhui
city: Beijing
country: China
facility: Beijing Tongren Hospital affiliated to Capital Medical University
state: Beijing
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
city: Chongqing
country: China
facility: The Second Affiliated Hospital of Army Medical University, PLA
state: Chongqing
city: Chongqing
country: China
facility: Army Special Medical Center of Peoples Liberation Army
state: Chongqing
city: Fuzhou
country: China
facility: Fujian Medical University Union Hospital
state: Fujian
city: Fuzhou
country: China
facility: Mengchao Hepatobiliary Hospital of Fujian Medical University
state: Fujian
city: Guangzhou
country: China
facility: Sun Yat-Sen University Cancer Center
state: Guangdong
city: Jiangmen
country: China
facility: Jiangmen Central Hospital
state: Guangdong
city: Shijiazhuang
country: China
facility: The 4th Hospital of Hebei Medical University
state: Hebei
city: Harbin
country: China
facility: Affiliated Cancer Hospital of Harbin Medical University
state: Heilongjiang
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology
state: Hubei
city: Wuhan
country: China
facility: Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
state: Hubei
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
city: Yangzhou
country: China
facility: Subei Peoples Hospital
state: Jiangsu
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
state: Jiangxi
city: Changchun
country: China
facility: Jilin Cancer Hospital
state: Jilin
city: Jinan
country: China
facility: Jinan Central Hospital
state: Shandong
city: Jinan
country: China
facility: Shandong Tumor Hospital
state: Shandong
city: Linyi
country: China
facility: Linyi Cancer Hospital
state: Shandong
city: Shanghai
country: China
facility: Shanghai Chest Hospital
state: Shanghai
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
city: Taiyuan
country: China
facility: Shanxi Province Cancer Hospital
state: Shanxi
city: Chengdu
country: China
facility: West China Hospital of Sichuan University
state: Sichuan
city: Hangzhou
country: China
facility: The First Affiliated Hospital Zhejiang University School of Medicine
state: Zhejiang
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University School of Medicine
state: Zhejiang
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
city: Taizhou
country: China
facility: Taizhou Hospital of Zhejiang Province
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
city: Beijing
country: China
facility: Beijing Chest Hospital, Capital Medical University
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
city: Tianjin
country: China
facility: Tianjin Peoples Hospital
city: Weihai
country: China
facility: Weihai Municipal Hospital
city: Brno
country: Czechia
facility: Fakultni nemocnice Brno
city: Brno
country: Czechia
facility: Masarykuv onkologicky ustav
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc
city: Ostrava-Vitkovice
country: Czechia
facility: Nemocnice Agel Ostrava-Vitkovice as
city: Praha 2
country: Czechia
facility: Vseobecna fakultni nemocnice v Praze
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Grenoble
country: France
facility: Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon
city: Lille Cedex
country: France
facility: Centre Hospitalier Régional Universitaire de Lille - Institut Coeur Poumon
city: Limoges Cedex
country: France
facility: Centre Hospitalier Regional Universitaire de Limoges - Hopital Dupuytren
city: Lyon
country: France
facility: Centre Leon Berard
city: Marseille Cedex 20
country: France
facility: Centre Hospitalier Universitaire Nord
city: Paris
country: France
facility: Institut Curie
city: Pierre-Benite cedex
country: France
facility: Centre Hospitalier Lyon Sud
city: Rennes Cedex 9
country: France
facility: Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
city: Strasbourg Cedex
country: France
facility: Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil
city: Toulouse Cedex 9
country: France
facility: Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
city: Villejuif
country: France
facility: Gustave Roussy
city: Berlin
country: Germany
facility: Charite Universitaetsmedizin Berlin, Campus Virchow
city: Dresden
country: Germany
facility: Universitaetsklinikum Dresden
city: Essen
country: Germany
facility: Universitaetsklinikum Essen
city: Gauting
country: Germany
facility: Asklepios Fachkliniken Muenchen Gauting
city: Grosshansdorf
country: Germany
facility: LungenClinic Grosshansdorf GmbH
city: Koeln
country: Germany
facility: Universitaetsklinikum Koeln
city: Stuttgart
country: Germany
facility: Robert-Bosch-Krankenhaus
city: Wuerzburg
country: Germany
facility: Universitaetsklinikum Wuerzburg
city: Athens
country: Greece
facility: Saint Savas Hospital
city: Athens
country: Greece
facility: Henry Dunant Hospital Center
city: Athens
country: Greece
facility: Thoracic General Hospital Of Athens Sotiria
city: Athens
country: Greece
facility: Alexandra Hospital
city: Heraklion - Crete
country: Greece
facility: University Hospital of Heraklion
city: Patra
country: Greece
facility: Olympion Therapeftirio General Clinic Of Patras
city: Thessaloniki
country: Greece
facility: Saint Luke Hospital
city: Thessaloniki
country: Greece
facility: European Interbalkan Medical Center
city: Budapest
country: Hungary
facility: Semmelweis Egyetem
city: Budapest
country: Hungary
facility: Orszagos Koranyi Pulmonologiai Intezet
city: Gyongyos
country: Hungary
facility: Matrai Gyogyintezet
city: Szekesfehervar
country: Hungary
facility: Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz
city: Tatabanya
country: Hungary
facility: Komarom-Esztergom Varmegyei Szent Borbala Korhaz
city: Torokbalint
country: Hungary
facility: Reformatus Pulmonologiai Centrum
city: Dublin
country: Ireland
facility: Beaumont Hospital
city: Haifa
country: Israel
facility: Rambam Medical Center
city: Jerusalem
country: Israel
facility: Hadassah Ein-Kerem Medical Center
city: Kfar Saba
country: Israel
facility: Meir Medical Center
city: Petah Tikva
country: Israel
facility: Rabin Medical Center
city: Bergamo
country: Italy
facility: Humanitas Gavazzeni
city: Catanzaro
country: Italy
facility: Azienda Ospedaliera Universitaria Renato Dulbecco
city: Genova
country: Italy
facility: Ospedale Policlinico San Martino IRCCS
city: Meldola (FC)
country: Italy
facility: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
city: Orbassano
country: Italy
facility: Azienda Ospedaliera Universitaria San Luigi Gonzaga
city: Roma
country: Italy
facility: Azienda Ospedaliera San Giovanni Addolorata
city: Nagoya-shi
country: Japan
facility: National Hospital Organization Nagoya Medical Center
state: Aichi
city: Nagoya-shi
country: Japan
facility: Aichi Cancer Center
state: Aichi
city: Kashiwa-shi
country: Japan
facility: National Cancer Center Hospital East
state: Chiba
city: Matsuyama-shi
country: Japan
facility: National Hospital Organization Shikoku Cancer Center
state: Ehime
city: Kurume-shi
country: Japan
facility: Kurume University Hospital
state: Fukuoka
city: Sapporo-shi
country: Japan
facility: National Hospital Organization Hokkaido Cancer Center
state: Hokkaido
city: Akashi-shi
country: Japan
facility: Hyogo Cancer Center
state: Hyogo
city: Yokohama-shi
country: Japan
facility: Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
state: Kanagawa
city: Sendai-shi
country: Japan
facility: Sendai Kousei Hospital
state: Miyagi
city: Niigata-shi
country: Japan
facility: Niigata Cancer Center Hospital
state: Niigata
city: Okayama-shi
country: Japan
facility: Okayama University Hospital
state: Okayama
city: Hirakata-shi
country: Japan
facility: Kansai Medical University Hospital
state: Osaka
city: Osaka-shi
country: Japan
facility: Osaka International Cancer Institute
state: Osaka
city: Osakasayama-shi
country: Japan
facility: Kindai University Hospital
state: Osaka
city: Hidaka-Shi
country: Japan
facility: Saitama Medical University International Medical Center
state: Saitama
city: Sunto-gun
country: Japan
facility: Shizuoka Cancer Center
state: Shizuoka
city: Bunkyo-ku
country: Japan
facility: Juntendo University Hospital
state: Tokyo
city: Chuo-ku
country: Japan
facility: National Cancer Center Hospital
state: Tokyo
city: Koto-ku
country: Japan
facility: The Cancer Institute Hospital of Japanese Foundation for Cancer Research
state: Tokyo
city: Wakayama-shi
country: Japan
facility: Wakayama Medical University Hospital
state: Wakayama
city: Cheongju Chungbuk
country: Korea, Republic of
facility: Chungbuk National University Hospital
city: Goyang-si Gyeonggi-do
country: Korea, Republic of
facility: National Cancer Center
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Hospital
city: Jinju-si
country: Korea, Republic of
facility: Gyeongsang National University Hospital
city: Seongnam-si, Gyeonggi-do
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea Seoul St Marys Hospital
city: Ulsan
country: Korea, Republic of
facility: Ulsan University Hospital
city: Kuantan
country: Malaysia
facility: Hospital Tengku Ampuan Afzan
state: Pahang
city: Kuching
country: Malaysia
facility: Sarawak General Hospital
state: Sarawak
city: Kuala Lumpur
country: Malaysia
facility: University Malaya Medical Centre
state: Wilayah Persekutuan
city: Ciudad de México
country: Mexico
facility: Oncare
state: Distrito Federal
city: Mexico City
country: Mexico
facility: Health Pharma Professional Research SA de CV
state: Distrito Federal
city: Tlajomulco de Zúñiga
country: Mexico
facility: coi Centro Oncologico Internacional sapi de cv
state: Jalisco
city: Groningen
country: Netherlands
facility: Universitair Medisch Centrum Groningen
city: Leiden
country: Netherlands
facility: Leids Universitair Medisch Centrum
city: Rotterdam
country: Netherlands
facility: Erasmus Medisch Centrum
city: Utrecht
country: Netherlands
facility: Universitair Medisch Centrum Utrecht
city: Bystra
country: Poland
facility: Centrum Pulmonologii i Torakochirurgii w Bystrej
city: Krakow
country: Poland
facility: Szpital Specjalistyczny imienia Ludwika Rydygiera w Krakowie Sp zoo
city: Poznan
country: Poland
facility: Wielkopolskie Centrum Pulmonologii i Torakochirurgii imienia Eugenii i Janusza Zeylandow
city: Lisboa
country: Portugal
facility: Hospital da Luz, SA
city: Lisboa
country: Portugal
facility: Hospital Cuf Descobertas
city: Matosinhos
country: Portugal
facility: Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano
city: Porto
country: Portugal
facility: Hospital Cuf porto
city: Cluj Napoca
country: Romania
facility: Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
city: Craiova
country: Romania
facility: Centrul de Oncologie Sf Nectarie SRL
city: Iasi
country: Romania
facility: Institutul Regional de Oncologie Iasi
city: Timisoara
country: Romania
facility: SC Oncomed SRL
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore
city: Singapore
country: Singapore
facility: Tan Tock Seng Hospital
city: Malaga
country: Spain
facility: Hospital Regional Universitario de Malaga
state: Andalucía
city: Zaragoza
country: Spain
facility: Hospital Clinico Universitario Lozano Blesa
state: Aragón
city: Barcelona
country: Spain
facility: Hospital del Mar
state: Cataluña
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d Hebron
state: Cataluña
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
state: Cataluña
city: A Coruña
country: Spain
facility: Complexo Hospitalario Universitario A Coruna Hospital Teresa Herrera
state: Galicia
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro Majadahonda
state: Madrid
city: Madrid
country: Spain
facility: Fundacion Jimenez Diaz
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Chur
country: Switzerland
facility: Kantonsspital Graubuenden
city: Fribourg
country: Switzerland
facility: Freiburg Spital
city: Geneve 14
country: Switzerland
facility: Hopitaux universitaires de Geneve
city: Sankt Gallen
country: Switzerland
facility: Kantonsspital Sankt Gallen
city: Winterthur
country: Switzerland
facility: Kantonsspital Winterthur
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
city: Taichung
country: Taiwan
facility: Veterans General Hospital - Taichung
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi
city: Ankara
country: Turkey
facility: Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi
city: Ankara
country: Turkey
facility: Ankara Bilkent Sehir Hastanesi
city: Denizli
country: Turkey
facility: Pamukkale Universitesi Tip Fakultesi Hastanesi
city: Istanbul
country: Turkey
facility: Bagcilar Medipol Mega Universite Hastanesi
city: Istanbul
country: Turkey
facility: Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
city: Izmir
country: Turkey
facility: Ege Universitesi Tip Fakultesi Hastanesi
city: Izmir
country: Turkey
facility: Izmir Ekonomi Universitesi Medical Point Hastanesi
city: Malatya
country: Turkey
facility: Inonu Universitesi Turgut Ozal Tip Merkezi
city: London
country: United Kingdom
facility: University College London Hospital
city: London
country: United Kingdom
facility: Guys Hospital
city: Manchester
country: United Kingdom
facility: Christie Hospital
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: